Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Coviccine Trivalent XBB Vaccine Booster in Adults
NCT05911061Phase 3Not yet recruiting
- Sponsor
- WestVac Biopharma
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Protein Vaccines
01
Overview
Phase 3, randomised, double-blind trial of Coviccine Trivalent XBB in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by WestVac Biopharma. Primary endpoints: Efficacy against COVID-19 and AE and AR. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
Coviccine Trivalent XBB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05911061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911061.